Overview

Begin With The Right Patients With Dual-Inhibition Action Therapy Through Vytorin for Newly Diagnosed Dyslipidemia Patients (0653A-172)(COMPLETED)

Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and tolerability of ezetimibe/simvastatin in patients newly diagnosed with dyslipidemia.
Phase:
Phase 4
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Ezetimibe
Ezetimibe, Simvastatin Drug Combination
Simvastatin